Identification of metabolic markers predictive of prediabetes in a Korean population

Abstract

Prediabetes (PD) is a high-risk state of developing type 2 diabetes, and cardiovascular and metabolic diseases. Metabolomics-based biomarker studies can provide advanced opportunities for prediction of PD over the conventional methods. Here, we aimed to identify metabolic markers and verify their abilities to predict PD, as compared to the performance of the traditional clinical risk factor (CRF) and previously reported metabolites in other population-based studies. Targeted metabolites quantification was performed in 1723 participants in the Korea Association REsource (KARE) cohort, from which 500 normal individuals were followed up for 6 years. We selected 12 significant metabolic markers, including five amino acids, four glycerophospholipids, two sphingolipids, and one acylcarnitine, at baseline, resulting in a predicted incidence of PD with an area under the curve (AUC) of 0.71 during follow-up. The performance of these metabolic markers compared to that of fasting glucose was significantly higher in obese patients (body mass index: BMI ≥ 25 kg/m2, 0.79 vs. 0.58, P < 0.001). The combination with metabolic markers, CRF, and fasting glucose yielded the best prediction performance (AUC = 0.86). Our results revealed that metabolic markers were not only associated with the risk of PD, but also improved the prediction performance in combination with conventional approaches.

Small molecule metabolites: discovery of biomarkers and therapeutic targets

“…Interestingly, several studies showed that targeting metabolic enzymes could significantly inhibit tumors to promote an effective therapeutic intervention. 370 , 643 – 646 …”

Advanced Mass Spectrometry-Based Biomarker Identification for Metabolomics of Diabetes Mellitus and Its Complications

“…This analytical approach facilitates the prediction of metabolite levels within the body and timely diagnosis of physiological states. Consequently, metabolomics assumes a pivotal role in the prevention, diagnosis, and treatment of prediabetes and diabetes-related conditions [ 18 , 19 ]. The results of previous studies showed that increase in branched-chain amino acids (BCAAs) was negatively correlated with insulin sensitivity and insulin metabolic clearance and positively correlated with fasting insulin through untargeted metabolomics detection of BCAAs [ 20 ].…”

Explainable AI-prioritized plasma and fecal metabolites in inflammatory bowel disease and their dietary associations

“… 7 , 8 , 9 , 10 Studies have also strongly linked IBD development with factors such as the gut microbiome, 11 the use of antibiotics, 12 and diet. 12 Unraveling such biological complexity necessitates targeted-omics studies, with metabolomics recently helping to identify distinct disease-related patterns 13 , 14 , 15 , 16 , 17 and key differences between individuals with IBD and those without. 18 , 19 , 20 These differences have been observed as alterations in fecal short-chain fatty acids 21 and serological lipids, such as cholesterol levels and its lipoprotein levels, 22 , 23 and as changes in amino acid profiles, generally increased in feces 21 , 24 and decreased in serum or plasma, 25 , 26 as well as energy-related metabolites.…”